Abstract
Objective: To evaluate the effect of metformin on blood pressure and insulin sensitivity in non-diabetic, moderately obese, hypertensive patients.
Patients and methods: An 8-week double-blind, placebo-controlled randomised study with a 4-week placebo run-in period was performed. Euglycaemic hyperinsulinaemic clamp tests and 24-hour ambulatory blood pressure measurements were performed after the 4-week placebo run-in period and after the 8-week double-blind treatment in patients in either the metformin 1500mg a day (n = 11) or corresponding placebo (n = 10) group.
Results: Metformin administration did not decrease either 24-hour ambulatory or office blood pressure when compared with placebo. The office mean systolic/ diastolic (±standard deviation) blood pressures before and after treatments were 153 (±22)/96 (±4)mm Hg and 155 (±14)/94 (+6)mm Hg in the metformin group, and 153 (±30)/97 (± 9)mm Hg and 149 (± 18)/96 (± 9)mm Hg in the placebo group, respectively. Metformin significantly decreased fasting serum glucose concentrations from 5.7 (± 0.9) to 5.2 (± 0.4) mmol/L (p = 0.04), but did not affect the insulin sensitivity of the patients.
Conclusions: Metformin does not appear to have a place in the treatment of hypertension in non-diabetic individuals, at least in those with mild hypertension.
Similar content being viewed by others
Notes
1Use of tradenames is for product identification only and does not imply endorsement.
References
Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7
Ferrannini EF, Haffner SM, Stern MP. Essential hypertension: an insulin-resistant state. J Cardiovasc Pharmacol 1990; 15 Suppl. 5: S18–25
Lithell HOL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203–9
Berntorp K, Lindgärd F, Mattiasson I. Long-term effects on insulin sensitivity and sodium transport in glucose-intolerant hypertensive subjects when β-blockade is replaced by captopril treatment. J Hum Hypertens 1992; 6: 291–8
Schafer G. Biguanides: a review of history, pharmacodynamics and therapy. Diabetes Metab 1983; 9: 148–63
Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755–72
DeFronzo RA, Goodman AM, the Multicenter Metformin Study Group. Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 541–9
Nosadini R, Avogaro A, Trevisan R, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10: 62–7
DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294–301
Johnson AB, Webster JM, Sum CF, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993; 42: 1217–22
Perriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920–8
Hother-Nielsen O, Schmitz O, Andersen PH, et al. Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 1989; 120: 257–65
Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1998; 13: 696–704
Widen EIM, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992; 41: 354–8
Landin K, Tengborn L, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181–7
Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J Intern Med 1994; 235: 335–41
Giugliano D, DeRosa N, DiMaro G, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 1993; 16: 1387–90
Snorgaard O, Koeber L, Carlsen J. The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients. J Intern Med 1997; 242: 407–12
O’Brien E, Atkins N, Mee F, et al. Comparative accuracy of six ambulatory devices according to blood pressure levels. J Hypertens 1993; 11: 673–5
De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–23
Yki-Järvinen H. Action of insulin on glucose metabolism in vivo. Bailliere’s Clin Endocrinol Metab 1993; 7: 903–28
Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647–54
Uehara MH, Kohlmann NE, Zanella MT, et al. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 2001; 3: 319–25
Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991; 14 Suppl. 4: 39–47
DeFronzo RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173–94
Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203–9
Starke AAR. Determination of insulin sensitivity: methodological considerations. Cardiovasc Pharmacol 1992; 20 Suppl. 11: S17–21
Boden G, Chen X, DeSantis RA, et al. Effects of age and body fat on insulin resistance in healthy men. Diabetes Care 1993; 16: 728–33
Vuorinen-Markkola H, Yki-Järvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994; 78: 25–9
Acknowledgements
The assistance of Ms Elina Kahra in performing the glucose clamp studies and the office blood pressure measurements is gratefully acknowledged. Also the assistance of Dr Jarno Johansson and Dr Jan Sundell in performing the 24-hour ambulatory blood pressure measurements is acknowledged. We acknowledge Leiras Finland for the donation of the medication for the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kantola, I., Rouru, J., Malminiemi, K. et al. Effect of Metformin on Blood Pressure. Clin. Drug Investig. 22, 347–354 (2002). https://doi.org/10.2165/00044011-200222060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200222060-00001